ArticleFrontiers in oncology2025
Development of a predictive model for radiation pneumonitis based on plasma exosomal miR-200b-5p.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rs1347093 polymorphism contributes to radiation pneumonitis in lung cancer patients through regulating miR-216a-5p expression.Functional & integrative genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to explore the association between plasma exosomal miRNAs and the development of radiation pneumonitis (RP) in non-small cell lung cancer (NSCLC) patients who underwent radiotherapy, and develop a predictive model for symptomatic radiation pneumonitis (SRP) by integrating miRNA expression levels with clinical and dosimetric parameters. Methods: A total of 95 NSCLC patients, who were scheduled to receive definitive radiotherapy, were prospectively enrolled. Plasma exosomes were collected before the radiotherapy, and high-throughput sequencing followed by bioinformatics analysis was performed to identify the candidate miRNAs associated to SRP. Then, the expression levels of these miRNAs were validated using RT-qPCR. Afterwards, a predictive model for SRP was constructed using a nomogram, which combined the miRNA expression data with the clinical and dosimetric factors. Results: Among the 95 patients, 20 (21.10%) patients developed SRP. The high-throughput sequencing revealed 220 differentially expressed miRNAs. Among these miRNAs, 168 miRNAs were upregulated and 52 miRNAs were downregulated in SRP patients ( Conclusion: The combination of lung V5 >46.36%, MLD >1120 cGy, and miR-200b-5p expression <0.445 can be used to effectively predict the occurrence of SRP in locally advanced NSCLC patients. This model can aid in the early identification of patients at high risk for RP, allowing for personalized treatment adjustments and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.